Drug intelligence / Profile preview

tacrolimus + ketoconazole

Development stage: Unknown
Lead developer: Astellas Pharma
Modality: Small Molecules
Administration: Oral

Overview

Tacrolimus + ketoconazole is a drug combination used in kidney transplant recipients. Ketoconazole increases blood levels of tacrolimus through inhibition of cytochrome P450 microsomal enzymes. This combination allows for significant reduction in tacrolimus dosage (typically 45-59%) while maintaining therapeutic immunosuppressive levels, which substantially reduces treatment costs. However, studies show conflicting results regarding safety and efficacy, with some research indicating an increased risk of acute rejection with long-term use.

Targets

CYP3A4 (Cytochrome P450 3A4)CYP3A5 (Cytochrome P450 family 3 subfamily A member 5)

Beyond the preview

Go deeper on tacrolimus + ketoconazole.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on tacrolimus + ketoconazole.

Explore the full profile